191 related articles for article (PubMed ID: 29460236)
1. A double-blind, randomised, placebo-controlled, cross-over study assessing the use of XEN-D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy.
Shunmugam SR; Sugihara C; Freemantle N; Round P; Furniss S; Sulke N
J Interv Card Electrophysiol; 2018 Apr; 51(3):191-197. PubMed ID: 29460236
[TBL] [Abstract][Full Text] [Related]
2. The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation.
Ford J; Milnes J; El Haou S; Wettwer E; Loose S; Matschke K; Tyl B; Round P; Ravens U
Heart Rhythm; 2016 Feb; 13(2):555-64. PubMed ID: 26455450
[TBL] [Abstract][Full Text] [Related]
3. First clinical trial of specific IKACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation.
Podd SJ; Freemantle N; Furniss SS; Sulke N
Europace; 2016 Mar; 18(3):340-6. PubMed ID: 26462707
[TBL] [Abstract][Full Text] [Related]
4. The effect of C-reactive protein reduction with a highly specific antisense oligonucleotide on atrial fibrillation assessed using beat-to-beat pacemaker Holter follow-up.
Sugihara C; Freemantle N; Hughes SG; Furniss S; Sulke N
J Interv Card Electrophysiol; 2015 Jun; 43(1):91-8. PubMed ID: 25711952
[TBL] [Abstract][Full Text] [Related]
5. A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers.
Ezekowitz MD; Ellenbogen KA; DiMarco JP; Kaszala K; Boddy A; Geba GP; Koren A
J Interv Card Electrophysiol; 2015 Mar; 42(2):69-76. PubMed ID: 25638303
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation.
Camm AJ; Dorian P; Hohnloser SH; Kowey PR; Tyl B; Ni Y; Vandzhura V; Maison-Blanche P; de Melis M; Sanders P
Eur Heart J Cardiovasc Pharmacother; 2019 Jan; 5(1):21-28. PubMed ID: 30052825
[TBL] [Abstract][Full Text] [Related]
7. Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor.
Ford J; Milnes J; Wettwer E; Christ T; Rogers M; Sutton K; Madge D; Virag L; Jost N; Horvath Z; Matschke K; Varro A; Ravens U
J Cardiovasc Pharmacol; 2013 May; 61(5):408-15. PubMed ID: 23364608
[TBL] [Abstract][Full Text] [Related]
8. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.
Reiffel JA; Camm AJ; Belardinelli L; Zeng D; Karwatowska-Prokopczuk E; Olmsted A; Zareba W; Rosero S; Kowey P;
Circ Arrhythm Electrophysiol; 2015 Oct; 8(5):1048-56. PubMed ID: 26226999
[TBL] [Abstract][Full Text] [Related]
9. Are implantable cardiac monitors the 'gold standard' for atrial fibrillation detection? A prospective randomized trial comparing atrial fibrillation monitoring using implantable cardiac monitors and DDDRP permanent pacemakers in post atrial fibrillation ablation patients.
Podd SJ; Sugihara C; Furniss SS; Sulke N
Europace; 2016 Jul; 18(7):1000-5. PubMed ID: 26585596
[TBL] [Abstract][Full Text] [Related]
10. The development of AF over time in patients with permanent pacemakers: objective assessment with pacemaker diagnostics demonstrates distinct patterns of AF.
Sugihara C; Veasey R; Freemantle N; Podd S; Furniss S; Sulke N
Europace; 2015 Jun; 17(6):864-70. PubMed ID: 26023175
[TBL] [Abstract][Full Text] [Related]
11. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade.
Aguilar M; Xiong F; Qi XY; Comtois P; Nattel S
Circulation; 2015 Dec; 132(23):2203-11. PubMed ID: 26499964
[TBL] [Abstract][Full Text] [Related]
12. Intermittent anticoagulation guided by continuous atrial fibrillation burden monitoring using dual-chamber pacemakers and implantable cardioverter-defibrillators: Results from the Tailored Anticoagulation for Non-Continuous Atrial Fibrillation (TACTIC-AF) pilot study.
Waks JW; Passman RS; Matos J; Reynolds M; Thosani A; Mela T; Pederson D; Glotzer TV; Zimetbaum P
Heart Rhythm; 2018 Nov; 15(11):1601-1607. PubMed ID: 29981863
[TBL] [Abstract][Full Text] [Related]
13. Bifocal versus unifocal right atrial pacing under plasma level controlled sotalol to prevent atrial fibrillation in patients with symptomatic sinus bradycardia and paroxysmal atrial fibrillation.
Stockburger M; Gerhardt L; Helms S; Schlegl M; Butter C
Herzschrittmacherther Elektrophysiol; 2007 Dec; 18(4):250-8. PubMed ID: 18084799
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.
Goette A; Schön N; Kirchhof P; Breithardt G; Fetsch T; Häusler KG; Klein HU; Steinbeck G; Wegscheider K; Meinertz T
Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):43-51. PubMed ID: 22157519
[TBL] [Abstract][Full Text] [Related]
15. Phased multipolar radiofrequency pulmonary vein isolation is as effective and safe as conventional irrigated point-to-point ablation. A prospective randomised 1-year implantable cardiac monitoring device follow-up trial.
Podd SJ; Sulke AN; Sugihara C; Furniss SS
J Interv Card Electrophysiol; 2015 Dec; 44(3):257-64. PubMed ID: 26310300
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR.
Piccini JP; Pritchett EL; Davison BA; Cotter G; Wiener LE; Koch G; Feld G; Waldo A; van Gelder IC; Camm AJ; Kowey PR; Iwashita J; Dittrich HC
Heart Rhythm; 2016 Sep; 13(9):1777-83. PubMed ID: 27108936
[TBL] [Abstract][Full Text] [Related]
17. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.
Davy JM; Herold M; Hoglund C; Timmermans A; Alings A; Radzik D; Van Kempen L;
Am Heart J; 2008 Sep; 156(3):527.e1-9. PubMed ID: 18760136
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
Beatch GN; Mangal B
BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
[TBL] [Abstract][Full Text] [Related]
19. In silico study on the effects of IKur block kinetics on prolongation of human action potential after atrial fibrillation-induced electrical remodeling.
Tsujimae K; Murakami S; Kurachi Y
Am J Physiol Heart Circ Physiol; 2008 Feb; 294(2):H793-800. PubMed ID: 18055524
[TBL] [Abstract][Full Text] [Related]
20. Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation.
Capucci A; Piangerelli L; Ricciotti J; Gabrielli D; Guerra F
Europace; 2016 Nov; 18(11):1698-1704. PubMed ID: 26893497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
